CClinicalTrials.gg
Not yet recruitingNCT06110741VaxInnateUpdated Nov 1, 2023

Evaluation of the Consequences of Poly Vaccination on Innate Immunity : Applications to a Military Population

An observational study in Vaccine Breakthrough Infections, sponsored by Direction Centrale du Service de Santé des Armées. Not yet recruiting. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Direction Centrale du Service de Santé des Armées · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
410
Ages
18 Years to 60 Years
Sex
All
01

Study summary

In this study, the poly vaccination of military personnel prior to deployment will be analyzed in terms of central, peripheral and long-lasting changes in innate immunity.

Analysis of monocyte immune training induced by vaccination will provide a better understanding of the indirect effects of vaccination and their persistence over time.

02

Conditions studied

  • Vaccine Breakthrough Infections
03

In context

Lead sponsor

Direction Centrale du Service de Santé des Armées is the lead sponsor of 93 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population is composed by healthy subjects which have to receive a vaccine update in order to be deployed

Inclusion criteria

  • french military personnel
  • >18yo
  • overseas deployment scheduled between 30 and 60 days after vaccination session
  • adult
  • able to give consent

Exclusion criteria

Exclusion Criteria:

  • unrectified military personnel
  • having received a live vaccine within 6 months prior to inclusion
  • having received an attenuated vaccine within 3 months prior to inclusion
  • pregnancy or breastfeeding
  • vaccine contraindication
  • major incapacity
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
410 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Sampling and survey group

    This group will complete questionnaires and participate in sample collection.

    Other: Blood and saliva sampling · Other: Survey

  • Survey group

    This group will only complete questionnaires

    Other: Survey

Interventions

  • OtherBlood and saliva sampling

    Collecting blood and saliva sample

  • OtherSurvey

    Collecting data on infectious diseases during the study period

06

What researchers measure

Primary outcomes

  1. Monocytes' functional reprogramming

    describing the functional reprogramming of monocytes following vaccination sessions among military personnel prior and after deployment

    Time frame: 11 months

Secondary outcomes

  1. Identify immune signatures

    Identifying immune signatures by comparing the functional reprogramming of monocytes by different vaccines and co vaccinations schemes

    Time frame: 11 months

  2. Time persistence

    Assess the persistence over time of the effects by follow-up after return from mission

    Time frame: 11 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06110741
Lead sponsor
Direction Centrale du Service de Santé des Armées
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Nov 2023 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
Apr 2026 (estimated)
Last update
Nov 1, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion